Here are the 10-K annual reports from Medpace Holdings, Inc. (MEDP) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow MEDP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MEDP filings page.
Medpace Holdings, Inc. is a global, full-service clinical contract research organization focused on Phase I–IV drug, biologic and medical device development. It provides integrated services from study design and feasibility through monitoring, labs, data science, pharmacovigilance and regulatory submissions across major therapeutic areas, especially oncology, metabolic disease, cardiology, AVAI and CNS.
The company serves a diversified base of small and mid-sized biopharmaceutical customers, with 82% of 2025 net revenue from small biopharma and 13% from mid-sized companies. Medpace reports approximately 6,200 employees across 46 countries and 28,381,283 common shares outstanding as of February 6, 2026, with non‑affiliate equity valued at about $7.0 billion as of June 30, 2025.
The filing highlights extensive risk factors, including contract cancellations, backlog conversion uncertainty, pricing pressure on margins, customer and therapeutic concentration, reliance on third-party vendors, evolving AI tools, cybersecurity threats to systems such as ClinTrak, global regulatory and anti‑corruption exposure, healthcare reform, and environmental, social and governance expectations.